One major challenge facing the modern world is the high mortality rate caused by diseases. These diseases are mostly chronic illnesses which haven’t had any or significant treatment breakthrough over the decades. This has led medical practitioners to come up with institutions that deal with the development of targeted therapy drug for such diseases. One of the most notable medical practitioners in this area is Dr. Clay Siegall. He is the founder and CEO of a biotech firm based in Seattle, dabbed as Seattle Genetics.

About Seattle Genetics

The firm focuses more on finding significant breakthroughs in medicine. Its way of achieving this, is by continually developing targeted therapy drugs for such diseases. Seattle Genetics was founded in the year 1998, and since then, Dr. Clay Siegall has steered the firm to a remarkable height. The firm developed the first FDA-approved antibody drug conjugate that has over the time received substantial approvals. The firm has strategically partnered with various drug manufacturers such as; Genentech, Pfizer, Bayer among others, in providing a wide range of variety of drugs that have proven to be remarkable. Under his leadership, the firm has seen great improvement in growth. During its early years in the industry the company had very few and not well known researchers. This soon changed over the years and currently it’s among the top players in the Research on Cancer.

Dr. Siegall does not plan to stop there yet, this is because the list of drugs in the development pipeline is still growing and need reliable firms such Seattle Genetics for a breakthrough. The struggle in offering effective treatment against these diseases still prove to be challenging but firms such as Seattle are still keeping up the fight. Dr. Clay Siegall will not stop nor give up on ensuring that we all have a healthier world.

Personal Details on Dr. Siegall

Dr. Siegall has involved himself in capital raising, whereby he managed to secure $675 million through public and private donors who were in support for his work. Early in his life, he previously worked with National Institutes of Health, for a period ranging from 1988 to 1991. He later joined a research institute, where he worked from 1991 to 1997, known as Bristol-myers Squibb Pharmaceutical Research Institute. His reputation and knowledge in his area of expertise allowed him to serve on the board of directors of a private biotechnology company Alder Biopharmaceuticals. In addition, Dr Siegall is an author and holds more than 70 publications and 15 patents under his name. He received his Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He surely is a force to reckon with in this industry.